Leeward Investments LLC MA Sells 224,104 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA reduced its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 37.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 376,104 shares of the life sciences company’s stock after selling 224,104 shares during the period. Leeward Investments LLC MA’s holdings in Integra LifeSciences were worth $6,834,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC raised its stake in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 425 shares in the last quarter. Northwest Investment Counselors LLC bought a new position in Integra LifeSciences during the third quarter valued at $73,000. Canada Pension Plan Investment Board purchased a new position in shares of Integra LifeSciences in the 2nd quarter worth $114,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after buying an additional 1,711 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Price Performance

Shares of IART opened at $25.51 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The company has a 50 day moving average price of $18.99 and a 200-day moving average price of $24.41. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The stock has a market capitalization of $1.98 billion, a PE ratio of -283.44, a PEG ratio of 0.82 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.25% and a negative net margin of 0.42%. The company had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. Integra LifeSciences’s revenue was down .4% on a year-over-year basis. Equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Bank of America dropped their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. JMP Securities cut their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Morgan Stanley raised their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Finally, Truist Financial cut their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.